Leerink Swann started coverage on shares of Inflarx (NASDAQ:IFRX) in a research report report published on Monday, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $31.00 price objective on the stock.
Separately, J P Morgan Chase & Co assumed coverage on shares of Inflarx in a research note on Monday. They set an overweight rating and a $30.00 price objective on the stock.
Shares of Inflarx (IFRX) opened at $18.05 on Monday. Inflarx has a 52 week low of $14.47 and a 52 week high of $22.48.
TRADEMARK VIOLATION WARNING: This report was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.chaffeybreeze.com/2017/12/08/inflarx-ifrx-now-covered-by-leerink-swann.html.
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company’s primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases.
Receive News & Ratings for Inflarx NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inflarx NV and related companies with MarketBeat.com's FREE daily email newsletter.